Brief: Puma Biotechnology Says Court Denied AstraZeneca's Motion For Invalidity

Puma Biotechnology

19/03/2024 22:20

March 19 (Reuters) - Puma Biotechnology Inc  PBYI.O :
    * PUMA BIOTECHNOLOGY INC - ON MARCH 18, 2024, COURT DENIED
ASTRAZENECA'S MOTION FOR INVALIDITY
    * PUMA BIOTECHNOLOGY-  COURT DENIED ASTRAZENECA'S MOTION FOR
SUMMARY JUDGMENT OF NON-INFRINGEMENT, EXCEPT AS TO PRE-ISSUANCE
DAMAGES
    * PUMA BIOTECHNOLOGY-COURT DENIED CO, WYETH & ASTRAZENECA
PHARMACEUTICALS,ASTRAZENECA AB & ASTRAZENECA PLC'S MOTIONS TO
EXCLUDE CERTAIN EXPERT TESTIMONY
    * PUMA BIOTECHNOLOGY INC - COMPANY WAS DISMISSED AS A
PLAINTIFF IN
MATTER, BUT REMAINS A COUNTERCLAIM-DEFENDANT IN ACTION
    * PUMA BIOTECHNOLOGY INC - CASE REMAINS ONGOING WITH A JURY
TRIAL
SCHEDULED TO BEGIN ON MAY 13, 202
    * PUMA BIOTECHNOLOGY-  HAS CONTRACTUAL RIGHTS TO RECOVER
MONETARY
DAMAGES IN ASTRAZENECA LITIGATION & RIGHTS ARE UNAFFECTED BY
COURT'S MARCH 18 ORDER

Source text for Eikon:  ID:n0001437749-24-008508 
Further company coverage:  PBYI.O 

 ((Reuters.Briefs@thomsonreuters.com;))